These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32055713)

  • 21. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
    Miller M; Pal A; Albusairi W; Joo H; Pappas B; Haque Tuhin MT; Liang D; Jampala R; Liu F; Khan J; Faaij M; Park M; Chan W; Graef I; Zamboni R; Kumar N; Fox J; Sinha U; Alhamadsheh M
    J Med Chem; 2018 Sep; 61(17):7862-7876. PubMed ID: 30133284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
    Cortese A; Vita G; Luigetti M; Russo M; Bisogni G; Sabatelli M; Manganelli F; Santoro L; Cavallaro T; Fabrizi GM; Schenone A; Grandis M; Gemelli C; Mauro A; Pradotto LG; Gentile L; Stancanelli C; Lozza A; Perlini S; Piscosquito G; Calabrese D; Mazzeo A; Obici L; Pareyson D
    J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-Silico molecular docking and simulation studies on novel chalcone and flavone hybrid derivatives with 1, 2, 3-triazole linkage as vital inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
    Thillainayagam M; Malathi K; Ramaiah S
    J Biomol Struct Dyn; 2018 Nov; 36(15):3993-4009. PubMed ID: 29132266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disruption of redox catalytic functions of peroxiredoxin-thioredoxin complex in Mycobacterium tuberculosis H37Rv using small interface binding molecules.
    Gurung AB; Das AK; Bhattacharjee A
    Comput Biol Chem; 2017 Apr; 67():69-83. PubMed ID: 28063347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Mundayat R; Stewart M; Alvir J; Short S; Ong ML; Keohane D; Rill D; Sultan MB
    Neurol Ther; 2018 Jun; 7(1):87-101. PubMed ID: 29633228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Maurer MS; Elliott P; Merlini G; Shah SJ; Cruz MW; Flynn A; Gundapaneni B; Hahn C; Riley S; Schwartz J; Sultan MB; Rapezzi C;
    Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lid opening and conformational stability of T1 Lipase is mediated by increasing chain length polar solvents.
    Maiangwa J; Mohamad Ali MS; Salleh AB; Rahman RNZRA; Normi YM; Mohd Shariff F; Leow TC
    PeerJ; 2017; 5():e3341. PubMed ID: 28533982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unwanted road to anaemia in transthyretin familial amyloid polyneuropathy may continue irrespective of tafamidis treatment.
    Ikeda T; Masuda T; Ueda M; Yamashita T; Misumi Y; Shinriki S; Ando Y
    Ann Clin Biochem; 2018 Sep; 55(5):571-575. PubMed ID: 29310464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathy.
    Buxbaum JN
    Degener Neurol Neuromuscul Dis; 2012; 2():165-173. PubMed ID: 30890886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential recognition of resveratrol isomers by the human estrogen receptor-alpha: molecular dynamics evidence for stereoselective ligand binding.
    Abou-Zeid LA; El-Mowafy AM
    Chirality; 2004 Mar; 16(3):190-5. PubMed ID: 14770416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
    Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
    J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of Molecular Details of Keap1-Nrf2 Inhibitors Using Molecular Dynamics and Umbrella Sampling Techniques.
    Londhe AM; Gadhe CG; Lim SM; Pae AN
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31726716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding characteristics of staphylococcal protein A and streptococcal protein G for fragment crystallizable portion of human immunoglobulin G.
    Lee HG; Kang S; Lee JS
    Comput Struct Biotechnol J; 2021; 19():3372-3383. PubMed ID: 34194664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Agonist and antagonist binding to the nuclear vitamin D receptor: dynamics, mutation effects and functional implications.
    Yaghmaei S; Roberts C; Ai R; Mizwicki MT; Chang CE
    In Silico Pharmacol; 2013; 1():2. PubMed ID: 25505647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational modeling of human coreceptor CCR5 antagonist as a HIV-1 entry inhibitor: using an integrated homology modeling, docking, and membrane molecular dynamics simulation analysis approach.
    Gadhe CG; Kothandan G; Cho SJ
    J Biomol Struct Dyn; 2013; 31(11):1251-76. PubMed ID: 23153179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors.
    Zanotti G; Cendron L; Folli C; Florio P; Imbimbo BP; Berni R
    FEBS Lett; 2013 Aug; 587(15):2325-31. PubMed ID: 23792159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receptor rigidity and ligand mobility in trypsin-ligand complexes.
    Guvench O; Price DJ; Brooks CL
    Proteins; 2005 Feb; 58(2):407-17. PubMed ID: 15578663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing Hispolon-based novel anticancer therapeutics against human (NF-κβ) using
    Paul M; Kumar Panda M; Thatoi H
    J Biomol Struct Dyn; 2019 Sep; 37(15):3947-3967. PubMed ID: 30295165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors.
    Tripathy S; Azam MA; Jupudi S; Sahu SK
    J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.